ClearPoint Neuro Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $7.639M Beat $6.994M Estimate
ClearPoint Neuro Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $7.639M Beat $6.994M Estimate
ClearPoint Neuro 2024年第一季度GAAP每股收益美元（0.16美元）超过预期（0.19美元），销售额763.9万美元超过预期的69.94万美元
ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 30.43 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $7.639 million which beat the analyst consensus estimate of $6.994 million by 9.23 percent. This is a 40.60 percent increase over sales of $5.433 million the same period last year.
ClearPoint Neuro（纳斯达克股票代码：CLPT）公布的季度亏损为每股0.16美元，比分析师普遍预期的0.19美元（0.19美元）高出15.79％。这比去年同期每股亏损0.23美元（0.23美元）增长了30.43％。该公司公布的季度销售额为763.9万美元，比分析师普遍预期的699.4万美元高出9.23％。这比去年同期的543.3万美元的销售额增长了40.60％。